OncoMed Pharmaceuticals Logo

Email this page: News Release

OncoMed Presents Immuno-Oncology Data for Combined Blockade of DLL4, VEGF and PD1 at the Society for Immunotherapy of Cancer Annual Meeting


Separate multiple addresses with commas. Maximum 200 characters.

These email addresses will be used to email the page on your behalf and will not be used by OncoMed Pharmaceuticals for any marketing purposes.


This helps OncoMed Pharmaceuticals prevent automated submissions.